Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link
Dow Jones Industrial Average
) is trading up 46 points (+0.3%) at 17,028 as of Tuesday, Jul 29, 2014, 10:36 a.m. ET. During this time, 117.1 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 305 million. The NYSE advances/declines ratio sits at 1,771 issues advancing vs. 1,068 declining with 221 unchanged.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Wednesday, July 30, 2014 is the ex-dividend date for Dow component
). Owners of shares as of market close today will be eligible for a dividend of 26 cents per share. At a price of $30.21 as of 10:36 a.m. ET, the dividend yield is 3.4% compared to the average Dow component yield of 2.6%.
The average volume for Pfizer has been 27.2 million shares per day over the past 30 days. Pfizer has a market cap of $192.57 billion and is part of the health care sector and drugs industry. Shares are down 1.7% year-to-date as of Monday's close.
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products. The company has a P/E ratio of 18.4, above the average drugs industry P/E ratio of 9.6.
- Practice your dividend trading strategies and win cash in our stock game.
TheStreet Ratings rates Pfizer as a
. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
- You can view the full Pfizer Ratings Report.